Hosted on MSN
Xenon projects top line X-TOLE2 data in early 2026 as enrollment surpasses target, expanding late-stage pipeline
Ian Mortimer, President and CEO, highlighted three critical priorities: completion of the Phase III X-TOLE2 study of azetukalner for focal onset seizures with top line data readout in early 2026; ...
Ian Mortimer, President and CEO, emphasized the nearing completion of patient recruitment for the X-TOLE2 Phase 3 epilepsy study and stated, "delivering data from our X-TOLE2 study remains our number ...
IAN MORTIMER, the PRESIDENT & CEO of $XENE, sold 16,217 shares of the company on 01-23-2025 for an estimated $649,977. We received data on the trade from a recent SEC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results